Iron Dextran Injection.

Ceruloplasmin, a copper enzyme, oxidises iron so transferrin can carry it to marrow. Copper status therefore sets how usable injected iron is.

Red cell precursors dividing rapidly need folate for DNA synthesis while iron supplies their heme. Iron delivery without folate leaves the other input limiting.

B12 regenerates the folate the marrow burns through during rapid red cell production, alongside the iron. All three inputs are checked together in practice.

ALA synthase uses pyridoxal 5-phosphate to begin heme assembly, the step where iron is incorporated. Delivered iron depends on that cofactor.

Parenteral iron bypasses the gut and downregulates uptake, so oral iron adds digestive burden with little gain. Practice is to pause oral iron rather than combine.

A parenteral iron load transiently raises redox-active iron that can start lipid peroxidation in membranes. Vitamin E interrupts that chain reaction.

Ascorbate reduces ferric iron and releases it from ferritin, aiding utilisation but also raising redox-active iron when circulating iron is high. The direction of the effect depends on iron load.

Oral iron and zinc compete at DMT1 in the intestinal brush border, which is why high-dose oral iron lowers zinc uptake from the same meal. Injected iron bypasses the intestine entirely, so that particular competition does not apply to a parenteral dose. The distinction matters because the interaction is real for one route and absent for the other, and mislabelling it either way is the common error.

Calcium taken with a meal reduces non-heme iron absorption from that meal, a well characterised food-iron interaction. An injected iron complex enters the plasma compartment directly and is not subject to it. Where oral and parenteral iron are used in sequence, the interaction applies only to the oral portion.

Manganese and iron share the DMT1 transporter and, at the systemic level, both bind transferrin, so iron status changes manganese handling and the same is true in the other direction. Raising body iron loading by injection alters that balance without any gut step involved. This is transport biochemistry, not a measured clinical endpoint.

Vitamin A status influences the release of iron from hepatic and reticuloendothelial stores into circulation, so retinol adequacy affects how much stored iron becomes usable. Iron delivered as a dextran complex is taken up by macrophages and enters exactly that storage compartment. The relationship is nutritional and describes iron handling rather than an outcome.

Flavin cofactors derived from riboflavin support the reductase steps involved in moving iron out of ferritin and across membranes. Riboflavin inadequacy therefore constrains iron utilisation regardless of how the iron arrived. This is cofactor biochemistry, and it applies to an injected iron load as much as to a dietary one.

Riboflavin-derived FAD and FMN support the reductase reactions that release iron from storage protein for incorporation into new haem. The relationship holds whatever the route by which the iron entered the body. It describes utilisation of iron already present, not absorption.

Galloylated catechins bind non-heme iron in the intestinal lumen and form complexes that are not absorbed, one of the strongest dietary inhibitors of iron uptake. That binding needs the two to meet in the gut, which an injected complex never does. The row is here because the interaction is routinely and wrongly applied to parenteral iron.

Tannins form insoluble complexes with ferric iron, which is the chemical basis of the classic tea-with-meals effect on iron uptake. The reaction requires luminal contact. An intramuscular or intravenous iron dextran dose is not exposed to it.

Quercetin's catechol and 3-hydroxy-4-keto arrangement binds iron, and the resulting complex behaves differently from free iron in redox terms. Depending on the ratio, flavonoid binding can either suppress or support iron-driven radical chemistry. That ambiguity is why the direction is written as modulating rather than protective.

Lactoferrin binds two ferric ions with very high affinity and holds them across a wide pH range, functioning as an iron-sequestering protein in secretions and at mucosal surfaces. It changes where free iron can go rather than adding to the total pool. Its relationship to a parenteral iron load is systemic handling, not absorption.

Free or loosely bound iron drives Fenton chemistry that generates hydroxyl radical, and reduced lipoic acid both chelates transition metals and participates in redox cycling. The net direction depends on the ratio and on whether the iron is protein-bound. This is chemistry of the iron pool rather than an effect on any measured endpoint.

Glutathione peroxidases are selenoenzymes and they are the main route for clearing hydrogen peroxide, the substrate that iron converts to hydroxyl radical. A rising iron load raises demand on that clearance capacity. Selenium adequacy is what keeps the enzymes at full complement, which is settled cofactor biochemistry.

Fermentable fructans lower colonic pH and have been described as improving the availability of divalent minerals in the large bowel. That mechanism is entirely about oral mineral intake. It has no bearing on an injected iron complex and is recorded here to make the boundary explicit.